WOBURN, Mass., May 26, 2022 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced multiple presentations at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago, IL from June 3 to June 7, 2022.
Details for the presentations are as follows:
Data presentation
Updated results from the skin cancer cohorts from an ongoing Phase 1/2 multi-cohort study of RP1, an enhanced potency oncolytic HSV, combined with nivolumab (IGNYTE)
- Session Title: Melanoma/Skin Cancers
- Session Date and Time: Monday, June 6, 2022, 1:15 PM-4:15 PM CDT
- Location: McCormick Place, Exhibit Hall A, Poster 146
- Abstract: 9553
Trial in progress presentations
A randomized, controlled, open-label, phase 2 study of cemiplimab ± RP1 in patients with advanced cutaneous squamous cell carcinoma (CERPASS)
- Session Title: Melanoma/Skin Cancers
- Session Date and Time: Monday, June 6, 2022, 1:15 PM-4:15 PM CDT
- Location: McCormick Place, Exhibit Hall A, Poster 184a
- Abstract: TPS9593
An open-label, multicenter, phase 1b/2 study of RP1, a first-in-class, enhanced potency oncolytic virus in solid organ transplant recipients with advanced cutaneous malignancies (ARTACUS)
- Session Title: Melanoma/Skin Cancers
- Session Date and Time: Monday, June 6, 2022, 1:15 PM-4:15 PM CDT
- Location: McCormick Place, Exhibit Hall A, Poster 187a
- Abstract: TPS9597
A phase 1 trial of RP2, a first-in-class, enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody as a single agent and combined with nivolumab in patients with advanced solid tumors
- Session Title: Developmental Therapeutics Immunotherapy
- Session Date and Time: Sunday, June 5, 2022, 8:00 AM-11:00 AM CDT
- Location: McCormick Place, Exhibit Hall A, Poster 339b
- Abstract: TPS2704
An open-label, multicenter, phase 1 study of RP3 as a single agent and in combination with nivolumab in patients (pts) with solid tumors
- Session Title: Developmental Therapeutics Immunotherapy
- Session Date and Time: Sunday, June 5, 2022, 8:00 AM-11:00 AM CDT
- Location: McCormick Place, Exhibit Hall A, Poster 340a
- Abstract: TPS2705
